Radiotherapy for localized hormone-refractory prostate cancer in Japan.
BACKGROUND
The role of radiotherapy for patients with localized hormone-refractory cancer has not been well documented.


METHODS
The Patterns of Care Study in Japan examined the records of 311 patients with prostate cancer treated with radiotherapy during the period 1996--1998. Of them, 61 patients (19.6%) with regionally localized hormone-refractory cancer were selected. Local progression or biochemical failure was observed after a median duration of 15.9 months of androgen deprivation. At the time of radiotherapy, 49 patients (80.4%) had T3-4 tumors and 15 (26.8%) had regional lymph node metastases. External beam radiotherapy was performed with a median total dose of 60 Gy.


RESULTS
Although distant metastases or regional lymph node metastases were seen in 22 patients (36.1), local progression was observed in one patient (1.6%). The five-year overall and progression-free survival rates were 51.6% and 43.5%, respectively.


CONCLUSIONS
Radiotherapy had an excellent local control rate for hormone-refractory cancer.
Nakamura
Katsumasa
K
Department of Clinical Radiology, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan. nakam@radiol.med.kyushu-u.ac.jp
Teshima
Teruki
T
Takahashi
Yutaka
Y
Imai
Atsushi
A
Koizumi
Masahiko
M
Mitsuhashi
Norio
N
Shioyama
Yoshiyuki
Y
Inoue
Toshihiko
T
D000368:Aged; D000369:Aged, 80 and over; D000726:Androgen Antagonists / Q000627:therapeutic use; D019008:Drug Resistance, Neoplasm; D004967:Estrogens / Q000627:therapeutic use; D006801:Humans; D007564:Japan; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D009919:Orchiectomy; D011471:Prostatic Neoplasms / Q000532:radiotherapy*; D012189:Retrospective Studies; D016896:Treatment Outcome
D000726:Androgen Antagonists; D004967:Estrogens